![DTB Podcast artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts123/v4/b7/ff/e6/b7ffe69d-a833-7d17-5986-c91912b9c87a/mza_4739691453721470086.png/100x100bb.jpg)
July 2022 - an e-letter, estradiol, APPGs, inclisiran and nitrofurantoin
DTB Podcast
English - June 28, 2022 03:46 - 29 minutes - 66.9 MB - ★★★★★ - 4 ratingsScience Health & Fitness Medicine dtb drug and therapeutics bulletin therapy medical evidence Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the July 2022 issue of DTB. They discuss the proposed reclassification of estradiol vaginal tablets from Prescription Only Medicine to a Pharmacy medicine (https://dtb.bmj.com/content/60/7/98) and review a study that assessed pharmaceutical industry funding of All Party Parliamentary Groups (https://dtb.bmj.com/content/60/7/100). They talk about the evidence for the lipid-lowering drug inclisiran and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/7/102). The editors also highlight a case report of acute lung toxicity caused by nitrofurantoin (https://dtb.bmj.com/content/60/7/108).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.